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ABSTRACT: Plasma or platelet serotonin concentration is commonly used to provide information about the serotonergic activity
in various psychiatric or neurological diseases. Some difficulties have been described in the measurement of serotonin (5-HT)
levels in plasma or platelets. We describe an isocratic liquid-chromatographic assay with amperometric detection for determination
of 5-HT in the platelet pellet and in platelet-rich and platelet-poor plasma (PRP and PPP) in sample sizes of 100 µL of plasma.
The method uses an RP18 column and an amperometric detector with a thin-layer type electrochemical flow cell, with glassy car-
bon electrode maintained at a potential of +0.600 V vs an Ag/AgCl reference electrode. Determinations were performed in the
presence or in the absence of plasma, since the biological matrix may affect the results. Different validation parameters were ana-
lysed: selectivity, accuracy, precision, linearity and stability. Reference values for 5-HT concentration in healthy adults (n = 12)
were 6.6 nmol/109 platelets, for the platelet pellet, and 5.5 nmol/109 platelets, for PRP. The 100 µL sample volume used for the
preparation of PPP did not make possible the determination of 5-HT levels with accuracy and precision. Copyright © 2004 John
Wiley & Sons, Ltd.
KEYWORDS: serotonin measurement; platelet serotonin; plasma serotonin
*Correspondence to: T. R. A. de Macedo, Instituto de Farmacologia
e Terapeutica Experimental, Faculdade de Medicina, Universidade
de Coimbra, 3004-054 Coimbra, Portugal.
E-mail: tice@ci.uc.pt
Abbreviations used: 5-HT, 5-hydroxytryptamine, serotonin; PPP,
platelet-poor plasma; PRP, platelet-rich plasma.
INTRODUCTION
A growing body of evidence suggests that serotonin (5-
hydroxytryptamine, 5-HT), a central and peripheral
neurotransmitter, plays an important role in regulating
various physiological functions associated with neuro-
logical or psychiatric disorders (Dreux and Launay,
1985; Veenstra-Vander Weele et al., 2000; Anderson
et al., 2002). Since the human brain is normally inacces-
sible during life for investigating various serotonergic
functions, blood platelets can serve as a peripheral
model for some of the central 5-HT presynaptic nerve
terminals. In fact, platelets accumulate, store and
release 5-HT in a manner analogous to the central
serotonergic synaptosomes (Stahl, 1977, 1985; Da Prada
et al., 1988). Investigations on the role of the platelet
serotonergic system in health volunteers, drug abusers
or in subjects with autism are a part of a program at
our laboratories (Macedo et al., 2000; Coutinho et al.,
2004). In the literature, normal values for human plate-
let 5-HT concentrations show wide variability, even
when specific methods well-characterized and fully
validated to quantify 5-HT were used (Flachaire et al.,
1990; Pussard et al., 1996). Since the platelets are sensit-
ive cells, one must be sure that the in vitro separation
of platelets from plasma is done without damaging
the cells (Middelkoop et al., 1993). Many investigators
prefer the whole-blood assay because measurements
in platelets and plasma offer some difficulties, due to
artefacts caused by preparation and/or sample con-
servation (Pussard et al., 1996; Xiao et al., 1998). Some
of the factors that should be considered when a sample-
preparation technique is selected are the complexity of
the matrix to be assayed and the concentration of the
endogenous compounds to be quantified.
In this work we developed and validated a method
for the quantitative analysis of 5-HT in isolated
platelets and plasma in human blood samples by
reversed-phase liquid chromatography with ampero-
metric detection. In the development of this method
particular attention was paid to the biological matrix
of the samples and sample handling. This method was
used to measure the 5-HT platelet concentrations in
platelet pellets, and in platelet-rich plasma (PRP) and
platelet-poor plasma (PPP) in humans.
EXPERIMENTAL
Chromatography and quantitation. The HPLC system
consisted of a 305 Gilson pump, a 231 Gilson auto sampler,
a Waters Spherisorb 5 µm ODS2 4.6 × 250 mm column and
a 141 Gilson electrochemical detector with a glassy carbon
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electrode set at 600 mV vs Ag/AgCl reference electrode. The
current range of the detector was set at 5 nA full scale.
The mobile phase was a degassed solution of 0.1 m
citric acid, and 0.1 m sodium acetate, pH 3.7, containing
10% methanol, 29 mg/L sodium octylsulphate, 55.8 mg/L
Na2EDTA and 0.17 mL/L dibutylamine, delivered at a flow-
rate of 1.0 mL/min. Peaks were recorded with a SP 4600
Spectra-Physics-Integrator. A peak area ratio method was
used for quantitation.
Reagents. 5-Hydroxytryptamine creatinine sulphate com-
plex and N-methyl-5-hydroxytryptamine (internal standard,
I.S.) were purchased from Sigma. Methanol for chromato-
graphy, dibutylamine for synthesis and perchloric acid 70%
(Suprapur) were obtained from Merck. All the other chem-
icals were of analytical grade and were purchased from
Merck.
Stock solutions and Standards. Stock solutions of 5-HT
(1.00 mg/mL) and I.S. (1.00 mg/mL) were prepared in 0.1 m
perchloric acid (HClO4). The first dilution of the stock solu-
tions at 10 µg/mL were stable for 15 days (5-HT) or one
week (I.S.) when stored in amber tubes at 4°C. The working
standards were prepared fresh by diluting the solutions at
10 µg/mL to make the required concentrations.
To determine 5-HT on the PRP a six-point calibration
standard curve, ranging from 85.1 to 851.3 nmol/L, was pre-
pared by spiking the human PPP with stock 5-HT and I.S.
(25 µL; 700 pmol) solutions. The standard curve used to
calculate the amount of 5-HT present in the platelet pellet
was prepared using five different concentrations of standard
solutions in 0.4 m HClO4, ranging from 22.7 to 567.5 nmol/L.
Previously, the standards were supplemented with I.S. (25 µL;
700 pmol). The quality control (QC) samples in PPP and in
0.4 m HClO4 at three concentration levels were prepared in a
similar manner.
Subjects. Twelve healthy adults (eight men and four women,
aged 22–27 years old), who had not taken 5-HT-containing
food during the 48 h period preceding blood sampling, were
used for the study. Serotonin concentrations in the platelet
pellet, PRP and PPP were determined.
Blood collection and sample handling. Venous blood was
collected into a 10 mL evacuated blood tube containing liquid
K3-EDTA (Middelkoop et al., 1993). Then the content of the
tubes was gently mixed and centrifuged at room temperature
for 10 min at 200 g (always within 2 h of the puncture). The
resulting PRP was transferred into a polypropylene tube and
100 µL was taken to count the number of platelets by using
a model AI Cellcounter 134. A 100 µL aliquot of PRP was
centrifuged at room temperature, for 15 min at 1000 g, to
separate the PPP from the platelet pellet.
One of the PRP, PPP and platelet pellet aliquots was
immediately analysed and the others were stored at −80°C
and analysed within 2 weeks.
Platelet pellet samples. The platelet pellet was resuspended
in 0.4 m HClO4 (975 µL) and supplemented with an I.S. solu-
tion (25 µL; 700 pmol) in a plastic tube. The tube was then
vortex-mixed for 30 s and stored at 4°C. To determine the
optimal 5-HT recovery time, 15 min, 1 and 2 h later the tube
was vortex-mixed again and centrifuged at 1000 g for 2 min,
at 4°C. A 100 µL aliquot of the resulting supernatant was
filtered and 25 µL were injected into the chromatograph.
Platelet-rich and platelet-poor plasma samples. To 100 µL
of the remaining PRP and PPP we added 25 µL of I.S. solu-
tion (700 pmol). After mixing, for plasma deproteinization
875 µL of 0.4 m HClO4 were added. The tubes were vortex-
mixed and stored at 4°C. Fifteen minutes and 1 and 2 h later,
the tubes containing PRP samples were vortex-mixed again
and centrifuged at 1000 g for 2 min, at 4°C. The tubes con-
taining PPP samples were maintained for 2 h before centri-
fugation, as indicated above. One hundred-microlitre aliquots
of the resulting supernatants were filtered and 25 µL were
injected into the chromatograph.
Data analysis and statistics. Serotonin concentrations
are expressed as nmol/109 platelets in platelet pellets and in
PRP, and as nmol/L in PPP. Values are expressed as mean
± standard deviation (SD). The precision was expressed as
relative standard deviation (RSD).
Student’s t-test was used to examine the statistical signific-
ance of the difference between 5-HT levels in the platelet
pellet and PRP. The effect of the incubation period on the
amount of 5-HT recovered from the PRP and platelet pellet
was analysed by one-way analysis of variance (ANOVA)
followed by Scheffe’s and Dunnett’s tests. The level of
significance was accepted for p < 0.05.
RESULTS AND DISCUSSION
Optimization of chromatographic conditions
The mobile phase that is usually used in our laboratory
to analyse catecholamines, their precursors and
metabolites in plasma and tissues is the same solution
used in the present work but contains a lower concen-
tration of n-octyl sodium sulphate (116.2 vs 29 mg/L
used here). With these conditions it is possible to
measure low catecholamine plasma levels, but regard-
ing 5-HT the chromatographic peaks are wider and the
retention times are longer (28 min). Therefore, experi-
ments were performed reducing the n-octyl sodium
sulphate proportion in the mobile phase, thus leading
to narrower and higher 5-HT peaks and shortened
retention time (8.2 min). When the n-octyl sodium
sulphate was eliminated from the mobile phase, inter-
ference of a minor peak preceding the I.S. retention
time was found in plasma samples.
Selectivity
According to the US Pharmacopoeia 24 (2000) ter-
minology and ICH guidelines (ICH, 1995), we decided
to use the term ‘selectivity’ when referring to this
validation parameter, reserving the term ‘specificity’ for
the procedures that are completely selective. ICH
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Figure 1. Selectivity chromatograms and typical chromatograms obtained from one healthy volunteer. (A) Blank platelet-
poor plasma; (B) blank platelet-poor plasma spiked with internal standard; (C) platelet-rich plasma sample corresponding
to a serotonin concentration of 7.42 nmol/109 platelets; and (D) platelet pellet sample containing 7.81 nmol/109 platelets.
Peak 1, serotonin; peak 2, N-methylserotonin (internal standard).
Table 1. Calibration curves data obtained for the analysis of serotonin in human plasma
Nominal concentration (nmol/L) Correlation
85.1 141.9 283.8 425.6 567.5 851.3 coefficient
Back-calculated concentration (nmol/L) Slope y-Intercept (r)
Mean (n = 3) 79.9 146.8 299.4 411.6 571.5 859.1 0.0014 0.0669 0.9948
SD 3.14 4.78 15.2 28.2 30.4 35.4 0.0001 0.0235 0.0028
RSD (%) 3.92 3.25 5.08 6.86 5.31 4.12 4.03 35.09 0.28
RE (%) −6.09 3.42 5.49 −3.29 0.71 0.91 — — —
Recovery (%) 93.9 103.4 105.5 96.7 100.7 100.9 — — —
guidelines define specificity as the ability to assess
unequivocally the analyte in the presence of compon-
ents that may be expected to be present, such as
impurities, degradation products and matrix compon-
ents. In practice, it is necessary to demonstrate that the
assay results are unaffected by the presence of potential
interferences.
PPP from 12 separate human plasmas were tested
and no endogenous interference was observed at the
retention time of I.S. Therefore, a minor peak of
endogenous 5-HT was observed in eight of the human
PPP samples (Fig. 1). The elimination of this inter-
ference is thus critical for quantitation of 5-HT in the
low-nmole range; the platelet 5-HT levels are so high
that endogenous interference is not significant. The
selectivity and/or specificity is considered adequate if
the interference does not exceed 20% of the peak for
the lower limit of quantitation (FDA, 2001).
Lower limit of quantitation and linearity
The calibration curve parameters for 5-HT in PPP and
in 0.4 m HClO4 from 3 days of validation are summar-
ized in Tables 1 and 2, respectively. The calibration
curves were linear for 5-HT in PPP, in the concen-
tration range 85.1–851.3 nmol/L, with an average
regression coefficient of 0.9948 ± 0.0028 (Table 1), and
for 5-HT in 0.4 m HClO4, in concentrations ranging
between 22.7 and 567.5 nmol/L, with a correlation
coefficient of 0.9993 ± 0.0002 (Table 2). The fit of the
calibration standards to the curves was assessed from
the relative error (RE, %): 100 × [(back-calculated
concentration from the regression line equation) −
(nominal concentration)]/(nominal concentration). For
5-HT in PPP and in 0.4 m HClO4, the differences for
mean back-calculated concentrations were less than
or equal to 6.09 and 2.66% of the theoretical values
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Table 2. Calibration curves data obtained for the analysis of serotonin in acidic medium (0.4 M HClO4)
Nominal concentration (nmol/L) Correlation
22.7 113.5 283.8 397.3 567.5 coefficient
Back-calculated concentration (nmol/L) Slope y-Intercept (r)
Mean (n = 3) 22.1 114.7 290.9 391.3 574.2 0.0016 0.0240 0.9993
SD 1.55 1.99 3.25 5.67 5.31 0 0.0018 0.0002
RSD (%) 6.99 1.73 1.12 1.45 0.93 0 7.37 0.02
RE (%) −2.60 1.04 2.66 −1.52 1.20 — — —
Recovery (%) 97.4 101.0 102.7 98.5 101.2 — — —
Table 3. Intra- and inter-day accuracy and precision of the QC samples for serotonin in
human plasma (PPP) and in acidic medium (0.4 M HClO4)
Concentration Recovery (%)
added (nmol/L) Day 1 Day 2 Day 3 (n) Inter-day
In PPP
141.9 Mean 102 107 101 (6) 104 (n = 18)
SD 8.80 7.74 10.49 9.06
RSD (%) 8.66 7.21 10.34 8.76
425.6 Mean 91.1 104 88.3 (6) 97.1 (n = 18)
SD 6.08 4.02 8.66 7.74
RSD (%) 6.67 3.87 9.82 7.74
709.4 Mean 97.1 101 95.5 (6) 99.6 (n = 18)
SD 4.75 7.61 6.17 6.77
RSD (%) 4.89 7.55 6.46 6.80
In HClO4 0.4 M
56.8 Mean 98.7 96.5 103 (4) 99.5 (n = 12)
SD 4.31 6.33 4.83 5.57
RSD (%) 4.36 6.57 4.68 5.60
141.9 Mean 95.5 99.1 99.2 (4) 98.2 (n = 12)
SD 3.02 4.94 3.70 3.76
RSD (%) 3.16 4.99 3.73 3.83
425.6 Mean 100 99.8 102 (4) 101 (n = 12)
SD 2.64 3.20 3.28 2.90
RSD (%) 2.64 3.21 3.22 2.88
(n = 3), in the 85.1–851.3 nmol/L and 22.7–567.5 nmol/
L concentration ranges, respectively (Tables 1 and 2).
The relative standard deviation (RSD) for 5-HT did
not exceed 6.86 and 6.99% in PPP and in 0.4 m
HClO4 calibration standards, respectively (Tables 1 and
2). The lower limit of quantitation (LLOQ) was
85.1 nmol/L using a 100 µL volume of human plasma
(Table 1). The LLOQ for 5-HT in 0.4 m HClO4 was set
at 22.7 nmol/L (Table 2). The predefined acceptable
limits of accuracy and precision for the LLOQ were 80
and 20%, respectively.
Accuracy and precision of the QC samples
The intra- and inter-assay accuracy and precision of
the method for 5-HT (in PPP and in 0.4 m HClO4) were
determined by analysing QC samples prepared on the
same day and on three different days respectively.
These QC samples were prepared at low, middle and
high concentrations of the corresponding calibration
curve. The analysis was done for six replicates at con-
centrations of 141.9, 425.6 and 709.4 nmol/L, for PPP,
and four replicates at concentrations of 56.8, 141.9 and
425.6 nmol/L for 0.4 m HClO4. The results are pres-
ented in Table 3. Accuracy was determined by calculat-
ing the mean recovery for the observed concentrations
as a percentage of the nominal concentrations in stand-
ard samples. Precision was assessed from the RSD of
the mean recoveries. The acceptable limits of recovery
and the corresponding RSD values for QC samples
were 85 and 15%, respectively. As shown in Table 3,
the precision and recovery for QC samples in PPP and
in 0.4 m HClO4 were within the tolerance limits. How-
ever, intra-day accuracy and precision show less vari-
ation in the QC samples in 0.4 m HClO4 when compared
with QC samples prepared in PPP. Therefore, the
intra-day mean recoveries (n = 4) varied from 95.5 to
103% and the corresponding RSD values varied from
2.64 to 6.57% over the 22.7–567.5 nmol/L concentration
range of 5-HT in 0.4 m HClO4. On the other hand, for
QC samples in PPP the intra-day mean recoveries (n =
6) varied from 88.3 to 107%, and the corresponding
Copyright © 2004 John Wiley & Sons, Ltd. Biomed. Chromatogr. 18: 739–744 (2004)
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Table 4. Effect of the incubation period with HClO4 (0.4 M), at 4°C, on the 5-HT concentra-
tion (nmol/109 platelets) measured in human platelet-rich plasma and platelet pellet
PRP samples Platelet pellet samples
Time after HClO4 5-HT RSD 5-HT RSD
addition (at 4°C) (nmol/109) (%) n (nmol/109) (%) n
15 min 3.6 ± 1.5* 41 10 4.9 ± 1.9* 39 10
1 h 5.5 ± 2.0 37 12 6.6 ± 1.5 23 12
2 h 5.7 ± 2.0 36 12 6.7 ± 1.6 24 10
24 h 5.7 ± 2.3 41 11 6.8 ± 2.0 30 12
Values are mean ± SD. * p < 0.05 compared with time 15 min, one-tailed Dunnet’s test.
PRP, platelet-rich plasma.
RSD values varied from 3.87 to 10.34% over the 85.1–
851.3 nmol/L concentration range of 5-HT in PPP.
Optimization of the extraction procedure
The 5-HT content of PRP and platelet pellets (contain-
ing 393 ± 100 × 103 platelets/µL PRP) was quantified
after incubation of the samples with HClO4 (0.4 m) for
15 min, 1 h and 2 h, at 4°C. The amount of 5-HT recov-
ered from both samples was maximal when the samples
were incubated with 0.4 m HClO4 for 1 h (Table 4). The
extracts were found to be stable at 4°C for 24 h, after
which there was a slow 5-HT and I.S. degradation,
which was less evident for 5-HT.
Stability
The stability of 5-HT and I.S. at room temperature
was evaluated over a time period that encompasses the
duration of sample handling and analytical running
time. In this study we have paid particular attention to
the concurrent time stability of 5-HT and I.S. because
indoleamines have poor stability at very low pH
(Thorré et al., 1997). RSD of peak areas (obtained
by subsequent injections of standard solutions: every
60 min for 6 h) for 5-HT and I.S. varied between 2.3
and 3.6%. The processed sample stability was evaluated
by comparing the extracted platelet samples that were
injected immediately after preparation (time 0), with
the samples that were re-injected 3 and 6 h after sitting
in the auto-sampler at room temperature. It was con-
cluded that the processed samples are stable at room
temperature for at least 6 h. The stability of the platelet
pellet and PRP samples, after 2 weeks of storage at
−80°C was evaluated as well. The stability evaluation
involved an analysis of the low, middle and high QC
samples that were stored at −80°C together with fresh
samples. The analysis was performed on the same day.
The peak area ratio of 5-HT/I.S was determined and
no differences were observed under the conditions
described. RSD values remained below 3 and 9% for
platelet pellet and PRP samples, respectively.
Normal values
The mean (±SD) value of the concentration of 5-HT in
the platelet pellet and in the PRP of 12 healthy adults
(eight men, four women, aged 22–27 years) was 6.6 ±
1.5 nmol per 109 platelets (range 4.4–9.0 nmol per 109
platelets) and 5.6 ± 2.0 nmol per 109 platelets (range
3.2–10.2 nmol per 109 platelets), respectively. Although
these values are not significantly different (p < 0.05),
the 5-HT range determined directly in platelet pellets
was narrower than that obtained in PRP.
The 5-HT concentration determined in PPP (n = 8)
was 26 ± 12 nmol/L (range 14–44 nmol/L). Serotonin
concentrations in PPP are very low in comparison with
those in platelets and the type of anticoagulant used
in blood collection is important to avoid in vitro release
of 5-HT from platelets. The higher 5-HT concen-
tration found is not in agreement with PPP normal
values published when K3-EDTA was used as anti-
coagulant (Middelkoop et al., 1993). An explanation
might be that the small plasma volume used in this
analytical procedure (100 µL) may not be enough to
allow the quantitation of 5-HT with good accuracy and
precision.
CONCLUSIONS
In this paper, the protocol for the validation of a chro-
matographic method to determine the 5-HT content in
different platelet samples was defined in accordance
with the recommendations provided by different inter-
national organizations. The criteria for data evaluation
and for acceptability of the results, including the matrix
effect, was examined and discussed. The complexity
of the matrix in PRP samples when compared with
platelet pellet samples resuspended in HClO4 (0.4 m)
should be considered. Although no differences were
observed in the 5-HT concentration in platelet pellets
and PRP samples, the results show that the method for
5-HT determination in platelet pellet samples is easy to
operate with better repeatability.
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